📗 Cite This Artifact
gp130/IL-6 Family Cytokine Signaling in Neurodegeneration
gp130/IL-6 Family Cytokine Signaling in Neurodegeneration
Overview
gp130/IL-6 Family Cytokine Signaling in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. [@alzheimers]
The gp130 family of cytokines constitutes a critical signaling network involved in immune regulation, neuronal survival, and inflammatory responses in the central nervous system. This family includes interleukin-6 (IL-6), interleukin-11 (IL-11), oncostatin M (OSM), leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), ciliary neurotrophic factor (CNTF), interleukin-27 (IL-27), and interleukin-35 (IL-35). These cytokines signal through gp130-containing receptor complexes and play complex roles in neurodegenerative diseases. [@transsignaling]
Receptor Complexes and Signaling Mechanisms
Classic Signaling vs. Trans-Signaling
The gp130 family cytokines can signal through two distinct mechanisms: [@leukemia]
Key Receptor Components
...
gp130/IL-6 Family Cytokine Signaling in Neurodegeneration
Overview
gp130/IL-6 Family Cytokine Signaling in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. [@alzheimers]
The gp130 family of cytokines constitutes a critical signaling network involved in immune regulation, neuronal survival, and inflammatory responses in the central nervous system. This family includes interleukin-6 (IL-6), interleukin-11 (IL-11), oncostatin M (OSM), leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), ciliary neurotrophic factor (CNTF), interleukin-27 (IL-27), and interleukin-35 (IL-35). These cytokines signal through gp130-containing receptor complexes and play complex roles in neurodegenerative diseases. [@transsignaling]
Receptor Complexes and Signaling Mechanisms
Classic Signaling vs. Trans-Signaling
The gp130 family cytokines can signal through two distinct mechanisms: [@leukemia]
Key Receptor Components
| Receptor | Primary Cytokines | Expression in CNS | [@jakstat]
|----------|------------------|-------------------| [@cardiotrophin]
| IL-6Rα/gp130 | IL-6 | Neurons, astrocytes, microglia | [@family]
| IL-11Rα/gp130 | IL-11 | Astrocytes, neurons | [@targeting]
| OSMR/gp130 | OSM | Astrocytes, microglia | [@neuroinflammation]
| LIFR/gp130 | LIF, CT-1, CNTF | Neurons, astrocytes | [@therapeutic]
| WSX-1/gp130 | IL-27 | Microglia, astrocytes | [@cntf]
| IL-12Rβ2/gp130 | IL-35 | Immune cells |
Downstream Signaling Pathways
JAK/STAT3 Pathway
The primary signaling pathway activated by gp130 cytokines:
- Acute phase proteins
- Anti-apoptotic proteins (Bcl-2, Bcl-xL)
- Negative feedback (SOCS3)
MAPK/ERK Pathway
Secondary pathway contributing to cell survival and proliferation:
PI3K/Akt Pathway
Cell survival pathway activated through gp130 :
Downstream Effects
- mTORC1: Protein synthesis, growth
- FOXO: Transcription factor activation
- GSK-3β: Glycogen metabolism
- NF-κB: Survival gene expression
Cross-talk Pathways
Role in Alzheimer's Disease
Chronic Neuroinflammation
IL-6 is elevated in Alzheimer's disease brains and CSF:
- Increased IL-6 in hippocampal neurons and surrounding glia
- Correlates with disease severity
- Contributes to chronic inflammatory state
Effects on Amyloid Pathology
- IL-6 can modulate amyloid precursor protein (APP) processing
- Trans-signaling promotes amyloid-beta production
- Microglial activation enhances phagocytosis but also inflammation
Effects on Tau Pathology
- JAK/STAT3 pathway can influence tau phosphorylation
- IL-6 affects GSK-3β activity
- Neuroinflammation drives tau spread
Synaptic Dysfunction
- IL-6 impairs long-term potentiation (LTP)
- Reduces dendritic spine density
- Affects synaptic plasticity genes
Role in Parkinson's Disease
Dopaminergic Neuron Vulnerability
- Elevated IL-6 in substantia nigra of PD patients
- LIF and CT-1 provide neuroprotection to dopaminergic neurons
- JAK/STAT3 activation promotes survival
Microglial Activation
- IL-6 drives microglial activation
- Chronic activation contributes to neurotoxicity
- LRRK2 mutations affect cytokine production
- TREM2 variants alter IL-6 responses
Neuroinflammation
- NLRP3 activation: IL-6 promotes inflammasome activation
- Cytokine cascade: IL-6 amplifies inflammatory responses
- Microglial priming: LRRK2 affects activation state
Alpha-Synuclein Interaction
- Inflammation accelerates alpha-synuclein aggregation
- Cytokines can propagate pathology
- Trans-synuclein spread enhanced by inflammatory environment
Role in ALS
Motor Neuron Inflammation
- Elevated IL-6 in ALS patients and models
- Correlates with disease progression
- Both protective and detrimental effects
- CSF IL-6 as biomarker
Role in Frontotemporal Dementia
TDP-43 Connection
- IL-6 signaling in FTD
- FUS pathology and gp130
- Autophagy dysregulation
- Inflammatory endpoints
C9orf72
- Repeat expansion affects signaling
- Dipeptide toxicity
- Immune dysregulation
Role in Multiple Sclerosis
Demyelination
- IL-6 in lesion formation
- OPC differentiation affected
- Remyelination failure
Clinical Trials
- IL-6R blockade being explored
- JAK inhibitors in trials
Astrocyte-Mediated Toxicity
- Astrocytic IL-6 contributes to motor neuron death
- Non-cell autonomous toxicity
- SOCS3 dysregulation affects feedback
- Astrocyte-neuron metabolic coupling disrupted
Glial-Neuronal Communication
- Astrocytes respond to gp130 cytokines
- Microglia produce IL-6 family ligands
- Oligodendrocyte survival affected
- NG2 glia respond to signaling
Therapeutic Potential
- JAK inhibitors show promise in preclinical models
- Anti-IL-6 strategies being explored
- Modulating trans-signaling vs. classic signaling
Therapeutic Targeting
Biological Agents
| Agent | Target | Status | Indications |
|-------|--------|--------|-------------|
| Tocilizumab | IL-6R | Approved (RA) | Being explored for ALS |
| Sarilumab | IL-6R | Approved (RA) | Preclinical |
| Siltuximab | IL-6 | Approved (MCD) | Being explored |
| Clazakizumab | IL-6 | Phase 2 | Preclinical |
JAK Inhibitors
| Agent | Target | Status |
|-------|--------|--------|
| Ruxolitinib | JAK1/2 | Clinical trials |
| Tofacitinib | JAK1/3 | Preclinical |
| Baricitinib | JAK1/2 | Clinical trials |
Modulation Strategies
Biomarkers
IL-6 Family as Biomarkers
| Marker | Disease | Change | Utility |
|--------|---------|--------|----------|
| IL-6 | ALS | ↑ in CSF | Progression |
| LIF | PD | ↓ in CSF | Diagnostic |
| CT-1 | AD | ↓ in CSF | Risk marker |
| sIL-6R | AD | ↑ in serum | Status |
Clinical Utility
- CSF/serum ratios for diagnosis
- Longitudinal monitoring
- Treatment response prediction
- Drug development endpoints
Mermaid Flowchart
Cross-Links
- [Interleukin](/entities/interleukin-6)
- [JAK](/mechanisms/jak-stat-parkinsons)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [TREM2 Signaling](/mechanisms/dopaminergic-neuron-vulnerability)
See Also
- [mTOR](/mechanisms/mtor-signaling-neurodegeneration)
- [Amyloid-β](/proteins/amyloid-beta-protein)
- [α-Synuclein](/proteins/alpha-synuclein)
- [Interleukin](/entities/interleukin-6)
- [JAK](/mechanisms/jak-stat-parkinsons)
- [Neuroinflammation](/mechanisms/neuroinflammation-pathway)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [TREM2 Signaling](/mechanisms/dopaminergic-neuron-vulnerability)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Recent Research Updates (2024-2026)
- [AA et al. 2024: Inhibition of IL-11 signalling extends mammalian healthspan and lifesp](https://pubmed.ncbi.nlm.nih.gov/39020175/)
- [XA et al. 2025: A neuroimmune circuit mediates cancer cachexia-associated apathy.](https://pubmed.ncbi.nlm.nih.gov/40208971/)
- [H et al. 2024: The Role of Pro-Inflammatory Cytokines in the Pathogenesis of Cardiova](https://pubmed.ncbi.nlm.nih.gov/38256155/)
- [Y et al. 2024: Regulation of Treg cells by cytokine signaling and co-stimulatory mole](https://pubmed.ncbi.nlm.nih.gov/38807592/)
- [A et al. 2024: Reappraisal of Adipose Tissue Inflammation in Obesity.](https://pubmed.ncbi.nlm.nih.gov/39287856/)
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | mechanisms-gp130-il6-family-signaling-neurodegeneration |
| kg_node_id | None |
| entity_type | mechanism |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-d072e4e711b7 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-gp130-il6-family-signaling-neurodegeneration'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-mechanisms-gp130-il6-family-signaling-neurodegeneration?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[gp130/IL-6 Family Cytokine Signaling in Neurodegeneration](http://scidex.ai/artifact/wiki-mechanisms-gp130-il6-family-signaling-neurodegeneration)
http://scidex.ai/artifact/wiki-mechanisms-gp130-il6-family-signaling-neurodegeneration